To quantify the tumorigenic effect of KRAS G12C mutation, we aggregated somatic variant calls from whole-exome sequencing of 1042 NSCLC tumors3 and from sequencing of 514 SCLC tumors (110 whole-genome sequencing, 139 whole-exome sequencing, and 265 panel sequencing of driver genes).3 This evidence concerns the gene KRAS and small cell lung carcinoma.